Literature DB >> 14511643

Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells.

Laura Pala1, Edoardo Mannucci, Anna Pezzatini, Silvia Ciani, Jacopo Sardi, Laura Raimondi, Agostino Ognibene, Angela Cappadona, Barbara G Vannelli, Carlo M Rotella.   

Abstract

Glucagon-like peptide-1 (GLP-1), a meal-stimulated gastrointestinal insulinotropic hormone inactivated by dipeptidyl peptidase-IV (DPP-IV), is reduced in type 2 diabetic patients. The present study shows that 2-week exposure of human glomerular endothelial cells to high glucose (22 mM) determines a highly significant increase in DPP-IV activity and mRNA expression, which cannot be entirely accounted for by hyperosmolarity. On the other hand, incubation of purified DPP-IV in a buffer solution added with high glucose does not affect enzyme activity. These results suggest that high glucose increases expression and activity of DPP-IV, possibly contributing to GLP-1 reduction in type 2 diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14511643     DOI: 10.1016/j.bbrc.2003.08.111

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

Review 1.  Glucagon-like peptide 1 (GLP-1) and metabolic diseases.

Authors:  C M Rotella; L Pala; E Mannucci
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

2.  Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.

Authors:  E Mannucci; L Pala; S Ciani; G Bardini; A Pezzatini; I Sposato; F Cremasco; A Ognibene; C M Rotella
Journal:  Diabetologia       Date:  2005-04-29       Impact factor: 10.122

3.  Effects of linagliptin on human immortalized podocytes: a cellular system to study dipeptidyl-peptidase 4 inhibition.

Authors:  Gianluca Miglio; Giovanna Vitarelli; Thomas Klein; Elisa Benetti
Journal:  Br J Pharmacol       Date:  2017-03-06       Impact factor: 8.739

4.  Potential of soluble CD26 as a serum marker for colorectal cancer detection.

Authors:  Oscar J Cordero; Monica Imbernon; Loretta De Chiara; Vicenta S Martinez-Zorzano; Daniel Ayude; Maria Paez de la Cadena; F Javier Rodriguez-Berrocal
Journal:  World J Clin Oncol       Date:  2011-06-10

5.  Glucagon-like peptide-1 response to meals and post-prandial hyperglycemia in Type 2 diabetic patients.

Authors:  E Mannucci; L Pala; M Monami; L Da Vico; G Bardini; I Dicembrini; S Ciani; C Lamanna; N Marchionni; C M Rotella
Journal:  J Endocrinol Invest       Date:  2009-09-11       Impact factor: 4.256

6.  High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV.

Authors:  C Marchetti; A Di Carlo; F Facchiano; C Senatore; R De Cristofaro; A Luzi; M Federici; M Romani; M Napolitano; M C Capogrossi; A Germani
Journal:  Diabetologia       Date:  2011-06-08       Impact factor: 10.122

Review 7.  DPP4 Activity, Hyperinsulinemia, and Atherosclerosis.

Authors:  Kaitlin M Love; Zhenqi Liu
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

8.  Microvesicles/exosomes as potential novel biomarkers of metabolic diseases.

Authors:  Günter Müller
Journal:  Diabetes Metab Syndr Obes       Date:  2012-08-07       Impact factor: 3.168

Review 9.  From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.

Authors:  Ilaria Dicembrini; Laura Pala; Carlo Maria Rotella
Journal:  Exp Diabetes Res       Date:  2011-06-23

10.  Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity.

Authors:  Yumei Wang; Sjoerd Landheer; Wiek H van Gilst; Aart van Amerongen; Hans-Peter Hammes; Robert H Henning; Leo E Deelman; Hendrik Buikema
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.